Streetbeat News

Price Targets

BIDU

Benchmark analyst Fawne Jiang has reiterated a 'Buy' rating on Baidu (NASDAQ:BIDU) and maintained a price target of $210.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 3:35 pm

F

A significant amount of unusual options activity has been detected for Ford Motor (NYSE:F), with a notably bullish stance. Of the 14 strange trades detected, 78% were opened with bullish expectations and 21% with bearish. The total amount for the 11 puts was $14,757,387 and for the 3 calls was $167,674. Whales have been targeting a price range from $8.0 to $12.0 for Ford Motor over the last 3 months. The stock is currently up 2.55% at $9.87. Morgan Stanley has downgraded its action to Overweight with a price target of $16.

Portfolio Pulse from Benzinga Insights

October 31, 2023 | 3:16 pm

LYFT

MoffettNathanson analyst Michael Morton has downgraded Lyft from Neutral to Sell and set a price target of $7.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 2:58 pm

UDR

B of A Securities analyst Joshua Dennerlein has downgraded UDR (NYSE:UDR) from Buy to Neutral and lowered the price target from $42 to $33.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 2:56 pm

MAA

B of A Securities analyst Joshua Dennerlein has downgraded Mid-America Apartment (NYSE:MAA) from Neutral to Underperform and lowered the price target from $136 to $112.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 2:54 pm

CPT

B of A Securities analyst Joshua Dennerlein has downgraded Camden Prop Trust (NYSE:CPT) from Neutral to Underperform and lowered the price target from $101 to $84.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 2:51 pm

PACB

Cantor Fitzgerald analyst Ross Osborn has upgraded Pacific Biosciences (NASDAQ:PACB) from Neutral to Overweight and lowered the price target from $14 to $11.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 2:37 pm

VRDN

RBC Capital analyst Gregory Renza has maintained an 'Outperform' rating on Viridian Therapeutics (NASDAQ:VRDN), but lowered the price target from $44 to $35.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 2:32 pm

THC

RBC Capital analyst Ben Hendrix has maintained an 'Outperform' rating on Tenet Healthcare (NYSE:THC), but lowered the price target from $87 to $72.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 2:31 pm

ZI

RBC Capital analyst Rishi Jaluria maintains a 'Sector Perform' rating on ZoomInfo Technologies (NASDAQ:ZI) but has lowered the price target from $22 to $16.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 2:28 pm